Completed Two Tenapanor Phase 2b Clinical Trials in Patients with Constipation-Predominant Irritable Bowel Syndrome (IBS-C) and in Chronic Kidney Disease Patients with Hyperphosphatemia (CKD-5D)Phase 2a Data for Tenapanor in CKD Patients Expected in 2Q 2015Conference Call and Webcast Today at 4:30 p.m. ET
FREMONT, Calif. , Feb. 18, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report its financial results for fourth quarter and full year ended December 31,
FREMONT, Calif. , Feb. 9, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that Mike Raab , President and Chief Executive Officer and David Rosenbaum Ph.D., Senior Vice
FREMONT, Calif. , Feb. 2, 2015 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal, and metabolic diseases, today announced that AstraZeneca's 161-patient Phase 2b clinical trial evaluating tenapanor in
FREMONT, Calif. , Dec. 1, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced the appointment of Jeremy S. Caldwell , Ph.D., as Executive Vice President and Chief Scientific
Phase 2 Programs for Lead Product Candidate Tenapanor Continue to Advance in Multiple IndicationsArdelyx Updates Projected Timing of Results from Phase 2b Study in ESRD patients with HyperphosphatemiaConference Call and Webcast Today at 4:30 p.m. ET
FREMONT, Calif. , Oct. 30, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that it will report third quarter 2014 financial results on Thursday, November 6, 2014 .
FREMONT, Calif. , Oct. 23, 2014 /PRNewswire/ -- Ardelyx, Inc. (NASDAQ: ARDX), a clinical-stage biopharmaceutical company focused on cardio-renal, gastrointestinal and metabolic diseases, today announced that Ardelyx , together with its development partner, AstraZeneca (NYSE:AZN, LON:AZN), will